Page 32 - HIV/AIDS Guidelines

9. Flandre P, Chappey C, Marcelin AG, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in
treatment-experienced patients with HIV-1 infection. J Infect Dis. 2007;195(3):392-398.
10. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected
treatment-experienced patients. AIDS. 2007;21(2):179-185.
11. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in
treatment-experienced patients. AIDS. 2006;20(6):847-853.
12. Verhofstede C, Wanzeele FV, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from
reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase
inhibitor-sensitive genotype. AIDS. 1999;13(18):2541-2546.
13. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected
patients with treatment failure. AIDS. 2000;14(18):2857-2867.
14. Devereux HL, Youle M, Johnson MA, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after
stopping therapy. AIDS. 1999;13(18):F123-127.
15. Benson CA, Vaida F, Havlir DV, et al. A randomized trial of treatment interruption before optimized antiretroviral therapy
for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006;194(9):1309-1318.
16. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J
Med. 2002;347(6):385-394.
17. Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline genotype as a predictor of virological failure to emtricitabine or
stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses. 2007;23(8):988-995.
18. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose
zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-
-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535-540.

19. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors
predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis.
2008;197(6):867-870.
20. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-
infected persons in 10 US cities. J Infect Dis. 2004;189(12):2174-2180.
21. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals
in Europe: implications for clinical management. J Infect Dis. 2005;192(6):958-966.
22. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre
observational study. BMJ. 2005;331(7529):1368.
23. Bennett D, McCormick L, Kline R, et al. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera.
Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; Feb 22-25, 2005; Boston, MA.
Abstract 674.

24. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1
subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-1212.

25. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in
antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8(1):1-8.

26. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive
populations and associate with reduced treatment efficacy. PLoS Med. 2008;5(7):e158.

27. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected,
antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2009;199(5):693-701.
28. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of
antiretroviral treatment failure. J Infect Dis. 2010;201(5):662-671.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents C-14

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.